NCT04865835View on ClinicalTrials.gov

A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 12, 2021

Primary Completion Date

May 3, 2022

Study Completion Date

May 3, 2022

Conditions
Schizophrenia
Interventions
DRUG

placebo

single dose of placebo

DRUG

SEP-363856

single dose of SEP 363856 100 mg

DRUG

metformin

metformin-HCl 850 mg

Trial Locations (2)

33334

At Fort Lauderdale Behavioral Health Center, Oakland Park

08053

Hassman Research Institute, Marlton

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY